Tags

Type your tag names separated by a space and hit enter

Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities.
Sci Rep. 2021 03 10; 11(1):5538.SR

Abstract

Understanding antibody responses to SARS-CoV-2 is indispensable for the development of containment measures to overcome the current COVID-19 pandemic. Recent studies showed that serum from convalescent patients can display variable neutralization capacities. Still, it remains unclear whether there are specific signatures that can be used to predict neutralization. Here, we performed a detailed analysis of sera from a cohort of 101 recovered healthcare workers and we addressed their SARS-CoV-2 antibody response by ELISA against SARS-CoV-2 Spike receptor binding domain and nucleoprotein. Both ELISA methods detected sustained levels of serum IgG against both antigens. Yet, the majority of individuals from our cohort generated antibodies with low neutralization capacity and only 6% showed high neutralizing titers against both authentic SARS-CoV-2 virus and the Spike pseudotyped virus. Interestingly, higher neutralizing sera correlate with detection of -IgG, IgM and IgA antibodies against both antigens, while individuals with positive IgG alone showed poor neutralization response. These results suggest that having a broader repertoire of antibodies may contribute to more potent SARS-CoV-2 neutralization. Altogether, our work provides a cross sectional snapshot of the SARS-CoV-2 neutralizing antibody response in recovered healthcare workers and provides preliminary evidence that possessing multiple antibody isotypes can play an important role in predicting SARS-CoV-2 neutralization.

Authors+Show Affiliations

Department of Microbiology, NYU Grossman School of Medicine, 430 East 29th Street, New York, NY, 10016, USA.Department of Microbiology, NYU Grossman School of Medicine, 430 East 29th Street, New York, NY, 10016, USA.Perlmutter Cancer Center, NYU Langone Health, New York, NY, 10016, USA. Department of Medicine, NYU Grossman School of Medicine, New York, NY, 10016, USA.Department of Microbiology, NYU Grossman School of Medicine, 430 East 29th Street, New York, NY, 10016, USA.Department of Pathology, NYU Grossman School of Medicine, New York, NY, 10016, USA.Department of Microbiology, NYU Grossman School of Medicine, 430 East 29th Street, New York, NY, 10016, USA.Perlmutter Cancer Center, NYU Langone Health, New York, NY, 10016, USA. Department of Biochemistry and Pharmacology, NYU Grossman School of Medicine, 521 1st Avenue, New York, NY, 10016, USA.Perlmutter Cancer Center, NYU Langone Health, New York, NY, 10016, USA.Department of Biochemistry and Pharmacology, NYU Grossman School of Medicine, 521 1st Avenue, New York, NY, 10016, USA.Perlmutter Cancer Center, NYU Langone Health, New York, NY, 10016, USA.Department of Biochemistry and Pharmacology, NYU Grossman School of Medicine, 521 1st Avenue, New York, NY, 10016, USA.Department of Microbiology, NYU Grossman School of Medicine, 430 East 29th Street, New York, NY, 10016, USA.New York University Langone Vaccine Center and New York University Grossman School of Medicine, New York, NY, 10016, USA.Department of Microbiology, NYU Grossman School of Medicine, 430 East 29th Street, New York, NY, 10016, USA.Perlmutter Cancer Center, NYU Langone Health, New York, NY, 10016, USA. Department of Pathology, NYU Grossman School of Medicine, New York, NY, 10016, USA.Department of Pathology, NYU Grossman School of Medicine, New York, NY, 10016, USA.New York University Langone Vaccine Center and New York University Grossman School of Medicine, New York, NY, 10016, USA.Department of Medicine, NYU Grossman School of Medicine, New York, NY, 10016, USA. New York University Langone Vaccine Center and New York University Grossman School of Medicine, New York, NY, 10016, USA. Office of Science and Research, NYU Langone Health, New York, NY, 10016, USA.Department of Microbiology, NYU Grossman School of Medicine, 430 East 29th Street, New York, NY, 10016, USA.Department of Microbiology, NYU Grossman School of Medicine, 430 East 29th Street, New York, NY, 10016, USA.Department of Pathology, NYU Grossman School of Medicine, New York, NY, 10016, USA.Perlmutter Cancer Center, NYU Langone Health, New York, NY, 10016, USA. Shohei.koide@nyulangone.org. Department of Biochemistry and Pharmacology, NYU Grossman School of Medicine, 521 1st Avenue, New York, NY, 10016, USA. Shohei.koide@nyulangone.org.Department of Microbiology, NYU Grossman School of Medicine, 430 East 29th Street, New York, NY, 10016, USA. Kenneth.stapleord@nyulangone.org.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33692390

Citation

Noval, Maria G., et al. "Antibody Isotype Diversity Against SARS-CoV-2 Is Associated With Differential Serum Neutralization Capacities." Scientific Reports, vol. 11, no. 1, 2021, p. 5538.
Noval MG, Kaczmarek ME, Koide A, et al. Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities. Sci Rep. 2021;11(1):5538.
Noval, M. G., Kaczmarek, M. E., Koide, A., Rodriguez-Rodriguez, B. A., Louie, P., Tada, T., Hattori, T., Panchenko, T., Romero, L. A., Teng, K. W., Bazley, A., de Vries, M., Samanovic, M. I., Weiser, J. N., Aifantis, I., Cangiarella, J., Mulligan, M. J., Desvignes, L., Dittmann, M., ... Stapleford, K. A. (2021). Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities. Scientific Reports, 11(1), 5538. https://doi.org/10.1038/s41598-021-84913-3
Noval MG, et al. Antibody Isotype Diversity Against SARS-CoV-2 Is Associated With Differential Serum Neutralization Capacities. Sci Rep. 2021 03 10;11(1):5538. PubMed PMID: 33692390.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities. AU - Noval,Maria G, AU - Kaczmarek,Maria E, AU - Koide,Akiko, AU - Rodriguez-Rodriguez,Bruno A, AU - Louie,Ping, AU - Tada,Takuya, AU - Hattori,Takamitsu, AU - Panchenko,Tatyana, AU - Romero,Larizbeth A, AU - Teng,Kai Wen, AU - Bazley,Andrew, AU - de Vries,Maren, AU - Samanovic,Marie I, AU - Weiser,Jeffrey N, AU - Aifantis,Ioannis, AU - Cangiarella,Joan, AU - Mulligan,Mark J, AU - Desvignes,Ludovic, AU - Dittmann,Meike, AU - Landau,Nathaniel R, AU - Aguero-Rosenfeld,Maria, AU - Koide,Shohei, AU - Stapleford,Kenneth A, Y1 - 2021/03/10/ PY - 2020/08/17/received PY - 2021/02/23/accepted PY - 2021/3/11/entrez PY - 2021/3/12/pubmed PY - 2021/4/1/medline SP - 5538 EP - 5538 JF - Scientific reports JO - Sci Rep VL - 11 IS - 1 N2 - Understanding antibody responses to SARS-CoV-2 is indispensable for the development of containment measures to overcome the current COVID-19 pandemic. Recent studies showed that serum from convalescent patients can display variable neutralization capacities. Still, it remains unclear whether there are specific signatures that can be used to predict neutralization. Here, we performed a detailed analysis of sera from a cohort of 101 recovered healthcare workers and we addressed their SARS-CoV-2 antibody response by ELISA against SARS-CoV-2 Spike receptor binding domain and nucleoprotein. Both ELISA methods detected sustained levels of serum IgG against both antigens. Yet, the majority of individuals from our cohort generated antibodies with low neutralization capacity and only 6% showed high neutralizing titers against both authentic SARS-CoV-2 virus and the Spike pseudotyped virus. Interestingly, higher neutralizing sera correlate with detection of -IgG, IgM and IgA antibodies against both antigens, while individuals with positive IgG alone showed poor neutralization response. These results suggest that having a broader repertoire of antibodies may contribute to more potent SARS-CoV-2 neutralization. Altogether, our work provides a cross sectional snapshot of the SARS-CoV-2 neutralizing antibody response in recovered healthcare workers and provides preliminary evidence that possessing multiple antibody isotypes can play an important role in predicting SARS-CoV-2 neutralization. SN - 2045-2322 UR - https://www.unboundmedicine.com/medline/citation/33692390/Antibody_isotype_diversity_against_SARS_CoV_2_is_associated_with_differential_serum_neutralization_capacities_ L2 - https://doi.org/10.1038/s41598-021-84913-3 DB - PRIME DP - Unbound Medicine ER -